BACKGROUND AND PURPOSE: Mounting evidence implicates matrix metalloproteinase (MMP) in the vascular dysfunction and remodelling associated with hypertension. We tested the hypothesis that treatment with pyrrolidine dithiocarbamate (PDTC), which interferes with NF-κB-induced MMPs gene transcription, could exert antihypertensive effects, prevent MMP-2 and MMP-9 up-regulation, and protect against the functional alterations and vascular remodelling of two-kidney, one clip (2K1C) hypertension. EXPERIMENTAL APPROACH: Sham-operated or hypertensive rats were treated with vehicle or PDTC (100 mg·Kg(-1) ·day(-1)) by gavage for 8 weeks. Systolic blood pressure (SBP) was monitored weekly. Aortic rings were isolated to assess endothelium-dependent relaxations. Quantitative morphometry of structural alterations of the aortic wall was carried out in haematoxylin/eosin sections. Formation of vascular reactive oxygen species (ROS), and inducible (i) NOS and phosphorylated-p65 NF-κB subunit expression were measured in the aortas. MMP-2 and MMP-9 aortic levels and gelatinolytic activity were determined by gelatin and in situ zymography and by immunofluorescence. KEY RESULTS: Treatment with PDTC attenuated the increases in SBP and prevented the endothelial dysfunction associated with 2K1C hypertension. Moreover, PDTC reversed the vascular aortic remodelling, the increases in aortic ROS levels and in iNOS and phosphorylated-p65 NF-κB expression found in 2K1C rats. These effects were associated with attenuation of 2K1C up-regulation of aortic MMP-2 and MMP-9 levels and gelatinolytic activity. CONCLUSION AND IMPLICATIONS: These findings suggest that PDTC down-regulates vascular MMPs and ameliorates vascular dysfunction and remodelling in renovascular hypertension, thus providing evidence supporting the suggestion that PDTC is probably a good candidate to be used to treat hypertension.
BACKGROUND AND PURPOSE: Mounting evidence implicates matrix metalloproteinase (MMP) in the vascular dysfunction and remodelling associated with hypertension. We tested the hypothesis that treatment with pyrrolidine dithiocarbamate (PDTC), which interferes with NF-κB-induced MMPs gene transcription, could exert antihypertensive effects, prevent MMP-2 and MMP-9 up-regulation, and protect against the functional alterations and vascular remodelling of two-kidney, one clip (2K1C) hypertension. EXPERIMENTAL APPROACH: Sham-operated or hypertensiverats were treated with vehicle or PDTC (100 mg·Kg(-1) ·day(-1)) by gavage for 8 weeks. Systolic blood pressure (SBP) was monitored weekly. Aortic rings were isolated to assess endothelium-dependent relaxations. Quantitative morphometry of structural alterations of the aortic wall was carried out in haematoxylin/eosin sections. Formation of vascular reactive oxygen species (ROS), and inducible (i) NOS and phosphorylated-p65 NF-κB subunit expression were measured in the aortas. MMP-2 and MMP-9 aortic levels and gelatinolytic activity were determined by gelatin and in situ zymography and by immunofluorescence. KEY RESULTS: Treatment with PDTC attenuated the increases in SBP and prevented the endothelial dysfunction associated with 2K1C hypertension. Moreover, PDTC reversed the vascular aortic remodelling, the increases in aortic ROS levels and in iNOS and phosphorylated-p65 NF-κB expression found in 2K1C rats. These effects were associated with attenuation of 2K1C up-regulation of aortic MMP-2 and MMP-9 levels and gelatinolytic activity. CONCLUSION AND IMPLICATIONS: These findings suggest that PDTC down-regulates vascular MMPs and ameliorates vascular dysfunction and remodelling in renovascular hypertension, thus providing evidence supporting the suggestion that PDTC is probably a good candidate to be used to treat hypertension.
Authors: C S Ceron; M M Castro; E Rizzi; M F Montenegro; V Fontana; M C O Salgado; R F Gerlach; J E Tanus-Santos Journal: Br J Pharmacol Date: 2010-03-19 Impact factor: 8.739
Authors: D N Muller; R Dechend; E M Mervaala; J K Park; F Schmidt; A Fiebeler; J Theuer; V Breu; D Ganten; H Haller; F C Luft Journal: Hypertension Date: 2000-01 Impact factor: 10.190
Authors: Michele M Castro; Elen Rizzi; Lívia Figueiredo-Lopes; Karla Fernandes; Lusiane M Bendhack; Dimitrius Leonardo Pitol; Raquel F Gerlach; Jose E Tanus-Santos Journal: Atherosclerosis Date: 2007-12-03 Impact factor: 5.162
Authors: Raquel C Antonio; Carla S Ceron; Elen Rizzi; Eduardo B Coelho; Jose E Tanus-Santos; Raquel F Gerlach Journal: Mol Cell Biochem Date: 2013-10-10 Impact factor: 3.396
Authors: Renata V Tiradentes; Cintia H Santuzzi; Erick Rg Claudio; Vinicius Mengal; Nyam F Silva; Henrique A F Neto; Nazaré S Bissoli; Glaucia R Abreu; Sonia A Gouvea Journal: Hypertens Res Date: 2015-03-05 Impact factor: 3.872
Authors: Cesar A Meschiari; Tatiane Izidoro-Toledo; Raquel F Gerlach; Jose E Tanus-Santos Journal: Mol Cell Biochem Date: 2013-03-03 Impact factor: 3.396
Authors: Cesar A Meschiari; Lucas C Pinheiro; Danielle A Guimaraes; Raquel F Gerlach; Jose E Tanus-Santos Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2015-11-28 Impact factor: 3.000
Authors: Marius C Staiculescu; Christopher Foote; Gerald A Meininger; Luis A Martinez-Lemus Journal: Int J Mol Sci Date: 2014-12-19 Impact factor: 5.923
Authors: Danielle A Guimarães; Elen Rizzi; Carla S Ceron; Lucas C Pinheiro; Raquel F Gerlach; Jose E Tanus-Santos Journal: Redox Biol Date: 2013-11-17 Impact factor: 11.799